Rare bleeding disorders - bleeding assessment tools, laboratory aspects and phenotype and therapy of FXI deficiency

Haemophilia

Volumn 20, Issue S4, 2014, Pages 71-75

  James, P ^a   Salomon, O ^b   Mikovic, D ^c   Peyvandi, F ^d,e  

^a QUEEN S UNIVERSITY   (Canada)

^b TEL AVIV UNIVERSITY   (Israel)

^c Blood Transfusion Institute of Serbia   (Serbia)

^d FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

^e UNIVERSITY OF MILAN   (Italy)

Author keywords

Bleeding assessment tools; Clinical severity; Factor XI treatment; Laboratory classification; Rare bleeding disorders

Indexed keywords

BLEEDING DISORDER; BLOOD CLOTTING; BLOOD CLOTTING DISORDER; BLOOD CLOTTING FACTOR 11 DEFICIENCY; CLINICAL ASSESSMENT TOOL; CLINICAL FEATURE; CONSANGUINEOUS MARRIAGE; DISEASE ASSOCIATION; DISEASE SEVERITY; HEMOPHILIA B; HUMAN; LABORATORY DIAGNOSIS; PHENOTYPE; POPULATION; PREVALENCE; PRIORITY JOURNAL; RARE BLEEDING DISORDER; REVIEW; BLOOD CLOTTING TEST; BLOOD COAGULATION DISORDERS, INHERITED; FACTOR XI DEFICIENCY; PROCEDURES; STANDARDS;

ANTIFIBRINOLYTIC AGENT; BLOOD CLOTTING FACTOR 11; BLOOD CLOTTING FACTOR 7A; RECOMBINANT PROTEIN;

ANTIFIBRINOLYTIC AGENTS; BLOOD COAGULATION DISORDERS, INHERITED; BLOOD COAGULATION TESTS; FACTOR VIIA; FACTOR XI; FACTOR XI DEFICIENCY; HUMANS; PHENOTYPE; RECOMBINANT PROTEINS;

EID: 84899506536     PISSN: 13518216     EISSN: 13652516     Source Type: Journal    
DOI: 10.1111/hae.12402     Document Type: Review

References (33)

1. Peyvandi F, Palla R, Menegatti M, Mannucci PM. Rare Bleeding Disorders: General Aspects of Clinical Features, Diagnosis, and Management. Semin Thromb Hemost 2009; 35: 349-55.
2. Sadler JE. Von Willebrand disease type 1: a diagnosis in search of a disease. Blood 2003; 101: 2089-93.
3. Mauer AC, Khazanov NA, Levenkova N et al. Impact of sex, age, race, ethnicity and aspirin use on bleeding symptoms in healthy adults. J Thromb Haemost 2011; 9: 100-8.
4. Higham JM, O'Brien PM, Shaw RW. Assessment of menstrual blood loss using a pictorial chart. Br J Obstet Gynaec 1990; 97: 734-9.
5. Srámek A, Eikenboom JC, Briët E et al. Usefulness of patient interview in bleeding disorders. Arch Inter Med 1995; 155: 1409-15.
6. Sadler JE, Rodeghiero F. Provisional criteria for the diagnosis of VWD type 1. J Thromb Haemost 2005; 3: 775-7.
7. Rodeghiero F, Castaman G, Tosetto A et al. The discriminant power of bleeding history for the diagnosis of type 1 von Willebrand disease: an international, multicenter study. J Thromb Haemost 2005; 3: 2619-26.
8. Bowman M, Mundell G, Grabell J et al. Generation and validation of the Condensed MCMDM-1VWD Bleeding Questionnaire for von Willebrand disease. J Thromb Haemost 2008; 6: 2062-6.
9. Rodeghiero F, Tosetto A, Abshire T et al. ISTH/SSC bleeding assessment tool: a standardized questionnaire and a proposal for a new bleeding score for inherited bleeding disorders. J Thromb Haemost 2010; 8: 2063-5.
10. Peyvandi F, Di Michele D, Bolton-Maggs PHB et al. Classification of rare bleeding disorders (RBDs) based on the association between coagulant factor activity and clinical bleeding severity. J Thromb Haemost 2012; 10: 1938-43.
11. Peyvandi F, Palla R, Menegatti M et al. Coagulation factor activity and clinical bleeding severity in rare bleeding disorders: results from the European Network of Rare Bleeding Disorders. J Thromb Haemost 2012; 10: 615-21.
12. Kulkarni A, Lee CA, Griffeon A et al. Disorders of menstruation and their effect on the quality of life in women with congenital factor VII deficiency. Haemophilia 2006; 12: 248-52.
13. Siboni SM, Spreafico M, Calò L et al. Gynaecological and obstetrical problems in women with different bleeding disorders. Haemophilia 2009; 15: 1291-9.
14. Tosetto A, Castaman G, Plug I et al. Prospective evaluation of the clinical utility of quantitative bleeding severity assessment in patients referred for hemostatic evaluation. J Thromb Haemost 2011; 9: 1143-8.
15. Azzam HAG, Goneim HR, El-Saddik AM et al. The condensed MCMDM-1 VWD bleeding questionnaire as a predictor of bleeding disorders in women with unexplained menorrhagia. Blood Coag Fibrinolysis 2012; 23: 311-5.
16. Shapiro SE, Phillips E, Manning RA et al. Clinical phenotype, laboratory features and genotype of 35 patients with heritable dysfibrinogenaemia. Br J Haematol 2013; 160: 220-7.
17. Duga S, Salomon O. Congenital factor XI deficiency: an update. Semin Thromb Hemost 2013; 39: 621-31.
18. Salomon O, Steinberg DM, Tamarin I et al. Plasma replacement therapy during labor is not mandatory for women with severe factor XI deficiency. Blood Coagul Fibrinolysis 2005; 16: 37-41.
19. Myers B, Pavord S, Kean L et al. Pregnancy outcome in Factor XI deficiency: incidence of miscarriage, antenatal and postnatal haemorrhage in 33 women with Factor XI deficiency. BJOG 2007; 114: 643-6.
20. Rugeri L, Quélin F, Chatard B et al. Thrombin generation in patients with factor XI deficiency and clinical bleeding risk. Haemophilia 2010; 16: 771-7.
21. Livnat T, Martinowita U, Mansharov U, Salomon O. Thrombin generation test can predict bleeding tendency in patients with severe factor XI deficiency. ASH -abstract 2013.
22. Zucker M, Salomon O, Seligsohn U, Wolberg AS. Abnormal plasma clot structure and stability distinguish bleeding risk in patients with severe factor XI deficiency. ISTH 2013 abstract No.1227.
23. Salomon O, Zivelin A, Livnat T et al. Prevalence, causes, and characterization of factor XI inhibitors in patients with inherited factor XI deficiency. Blood 2003; 101: 4783-8.
24. Mannucci PM, Bauer KA, Santagostino E et al. Activation of the coagulation cascade after infusion of a factor XI concentrate in congenitally deficient patients. Blood 1994; 15: 1314-9.
25. Boehlen F, Casini A, Pugin F, de Moerloose P. Pulmonary embolism and fatal stroke in a patient with severe factor XI deficiency after bariatric surgery. Blood Coagul Fibrinolysis 2013; 24: 347-50.
26. Quélin F, Trossaërt M, Sigaud M, Mazancourt PD, Fressinaud E. Molecular basis of severe factor XI deficiency in seven families from the west of France. Seven novel mutations, including an ancient Q88X mutation. J Thromb Haemost 2004; 2: 71-6.
27. Livnat T, Tamarin I, Mor Y et al. Recombinant activated factor VII and tranexamic acid are haemostatically effective during major surgery in factor XI-deficient patients with inhibitor antibodies. Thromb Haemost 2009; 102: 487-92.
28. Riddell A, Abdul-Kadir R, Pollard D et al. Monitoring low dose recombinant factor FVIIa therapy in patients with severe factor XI deficiency undergoing surgery. Thromb Haemost 2011; 106: 521-7.
29. Schulman S, Nemeth G. An illustrative case and a review on the dosing of recombinant factor VIIa in congenital factor XI deficiency. Hemophilia 2006; 12: 223-7.
30. O'Connell NM, Riddell AF, Pascoe G et al. Recombinant factor VIIa to prevent surgical bleeding in factor XI deficiency. Haemophilia 2008; 14: 775-81.
31. Salomon O, Steinberg DM, Seligshon U. Variable bleeding manifestations characterize different types of surgery in patients with severe factor XI deficiency enabling parsimonious use of replacement therapy. Haemophilia 2006; 12: 490-3.
32. Bolton Maggs PHB, Perry DJ, Chalmers EA. The rare coagulation disorders - review with guidelines for management from the United Kingdom Haemophilia Centre Doctors' Organisation. Haemophilia 2004; 10: 593-628.
33. Peyvandi F, Spreafico M. National and International registries of rare bleeding disorders. Blood Transfusion 2008; 6(Suppl2): s45-8.